Clinical Research Directory

Inclusion criteria are as follows: 1. Participants presented with hematemesis, melena, or other clinical manifestations suggestive of upper gastrointestinal bleeding within 5 days before screening. 2. Participants have endoscopic confirmation of a non-variceal source of upper gastrointestinal bleeding. 3. Participants are aged between 18 and 75 years. 4. Participants who are willing to participate in this clinical trial and sign the written informed consent. Exclusion criteria are as follows: 1. Participants have experienced failure of endoscopic hemostasis, rebleeding before randomization, or a requirement for immediate transcatheter arterial embolization or surgery at the time of eligibility assessment. 2. Participants have an active malignancy or malignancy expected to interfere with survival, outcome assessment, treatment adherence, or follow-up. 3. Participants have esophageal or gastric varices or portal hypertensive gastropathy identified during endoscopic examination. 4. Participants who are unable to swallow the study medication. 5. Participants have a history of partial or total gastrectomy, gastric bypass surgery, or other major surgery. 6. Severe organ dysfunction, including any of the following: Severe hepatic or renal impairment; Unstable or severe cardiovascular, respiratory, neurological, or other systemic disease. 7. Zollinger-Ellison syndrome. 8. Any contraindication to keverprazan or pantoprazole, including known hypersensitivity to either medication or any of their components. 9. Pregnancy or lactation. 10. Participation in another clinical study within 3 months before enrollment. 11. Other situations considered by the investigator as unsuitable for enrollment.